Vivoryon Therapeutics N.V. to Present at Upcoming Conferences

Rhea-AI Summary

Vivoryon Therapeutics N.V. announced that CEO Dr. Ulrich Dauer will present at significant investor conferences in March 2023. The events include the BioCapital Europe 2023 on March 9, the Barclays Global Healthcare Conference on March 16, and the German Biotechnology Days on March 29. A webcast of these presentations will be accessible on their website.

Vivoryon Therapeutics N.V. to Present at Upcoming Conferences

Halle (Saale) / Munich, Germany, February 21, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that Dr. Ulrich Dauer, CEO of Vivoryon Therapeutics, will present at the following investor conferences and industry events:

BioCapital Europe 2023
Date: March 9, 2023
Time: 09:40 am CET
Venue: Hotel Sofitel Legend The Grand Amsterdam; Amsterdam, The Netherlands

Barclays Global Healthcare Conference
Date: March 16, 2023
Time: 08:00 am EDT / 01:00 pm CET
Venue: Loews Miami Beach Hotel; Miami, USA

A webcast of the presentation will be available via the "Presentations & Webcasts" page in the Investor Relations section on the Company's website at www.vivoryon.com and will be archived on the Company's website for 30 days following the conference.

German Biotechnology Days (Deutsche Biotechnologietage) 2023
Date: March 29, 2023
Time: 02:00 pm CEST
Venue: RheinMain CongressCenter; Wiesbaden, Germany

###

About Vivoryon Therapeutics N.V.
Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases. We leverage our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. Beyond our lead program, varoglutamstat, which is in Phase 2 clinical development to treat Alzheimer’s disease, we have established a solid pipeline of orally available small molecule inhibitors for various indications including cancer, inflammatory diseases and fibrosis. www.vivoryon.com

Vivoryon Forward Looking Statements
This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of the Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.

For more information, please contact:

Investor Contact
Stern IR
Julie Seidel
Tel: +1 212-698-8684
Email: SternIR-Vivoryon@sternir.com

Media Contact
Trophic Communications
Valeria Fisher
Tel: +49 175 8041816
Email: vivoryon@trophic.eu

FAQ

What is the schedule for Vivoryon Therapeutics' upcoming conferences in March 2023?

Vivoryon Therapeutics will present at three key events in March 2023: BioCapital Europe on March 9, Barclays Global Healthcare Conference on March 16, and German Biotechnology Days on March 29.

Who is presenting at the Vivoryon Therapeutics conferences?

Dr. Ulrich Dauer, the CEO of Vivoryon Therapeutics, will be the presenter at the upcoming conferences.

Where can I watch the Vivoryon Therapeutics conference presentations?

Webcasts of the Vivoryon Therapeutics presentations will be available on their website and will be archived for 30 days following the events.

What is the focus of Vivoryon Therapeutics as a company?

Vivoryon Therapeutics focuses on developing innovative small molecule medicines to modulate the activity and stability of proteins altered in disease settings, with a lead program targeting Alzheimer’s disease.

What are the dates and venues for Vivoryon Therapeutics' conference presentations?

The conference dates and venues are: BioCapital Europe on March 9 at Hotel Sofitel Legend The Grand Amsterdam, Barclays Global Healthcare Conference on March 16 at Loews Miami Beach Hotel, and German Biotechnology Days on March 29 at RheinMain CongressCenter in Wiesbaden, Germany.